You are here: Industry Insights > Novartis

News List

New migraine results for both Allergan and Novartis pharmatimes
September 12, 2017
Allergan has announced new head-to-head data from an open label study in chronic migraine demonstrating that Botox (onabotulinumtoxinA) had a more favourable tolerability profile than Topamax (topiramate).
Melanoma treatment: Novartis posts success, Roche stumbles pharmafile
September 12, 2017
In a perfect example of the competitive nature of the pharmaceutical industry, just as one company posted success in one particular area, another company was forced to reveal its failure in the same patient group.
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018 americanpharmaceuticacreview
September 06, 2017
Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position.
Novartis’ Gilenya hits targets in paediatric MS trial pharmatimes
September 06, 2017
Novartis has released top-line data showing that Gilenya significantly reduced relapses in children and adolescents with multiple sclerosis.
Novartis celebrates success of Gilenya in paediatric multiple sclerosis pharmafile
September 06, 2017
Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod)
Novartis appointed Vasant Narasimhan as CEO, effective February 1, 2018 biospectrumasia
September 06, 2017
Before joining Novartis in 2005, he worked at McKinsey & Company. He received his medical degree from Harvard Medical School in the US and obtained a master's degree in public policy from Harvard's John F. Kennedy School of Government
Novartis appoints Vasant Narasimhan as CEO expressbpd
September 05, 2017
The Board of Directors of Novartis has appointed Vasant (Vas) Narasimhan, MD, Global Head of Drug Development and CMO, as CEO
Novartis announces new CEO europeanpharmaceuticalreview
September 05, 2017
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
Novartis crosses FDA finish line with monumental CAR-T leukemia approval fiercepharma
August 31, 2017
Novartis won FDA approval for its CAR-T drug Kymriah on Wednesday.
Novartis, Medicines for Malaria Venture launch patient trial for KAF156 pharmaasia
August 31, 2017
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection and blocking parasite transmission.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page